Perfil
Steffen Wagner is currently the Chief Executive Officer & Director at Advanz Pharma Corp.
Ltd.
He previously worked as the Executive Vice President-European Markets at STADA Arzneimittel AG.
Cargos activos de Steffen Wagner
Empresas | Cargo | Inicio |
---|---|---|
ADVANZ PHARMA CORP. LIMITED | Chief Executive Officer | 01/04/2022 |
Antiguos cargos conocidos de Steffen Wagner.
Empresas | Cargo | Fin |
---|---|---|
STADA ARZNEIMITTEL | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
STADA Arzneimittel AG
STADA Arzneimittel AG Pharmaceuticals: OtherHealth Technology STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the following segments: Generics, Consumer Healthcare, and Specialty. The Generics segment produces and distributes generic drugs. The Consumer Healthcare segment includes products such as OTC drugs, nutritional supplements and certain consumer healthcare products such as disinfectants and sunscreen. The Specialty segment includes branded generics, specialty generics, and biosimilars. Its brands include Zoflora, Grippostad, Nizoral, and Shampoo & Ladival. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany. | Health Technology |
Advanz Pharma Corp. Ltd.
Advanz Pharma Corp. Ltd. Pharmaceuticals: MajorHealth Technology ADVANZ PHARMA Corp. Ltd. is a pharmaceutical company engages in the provision of branded and unbranded products. The firm specializes in anti-Infectives and endocrinology therapy areas. It operates through the following segments: Advanz Pharma International; Advanz Pharma North America; and Corporate. The Advanz Pharma International segment include portfolio of branded and generic products that are sold to wholesalers, hospitals, and pharmacies. The Advanz Pharma North America segment comprises branded products and authorized generic contracts that focuses primarily on the U.S. pharmaceutical market. The Corporate segment represents the centralized costs. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in St. Helier, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Steffen Wagner